Below is Validea's guru fundamental report for SEAGATE TECHNOLOGY HOLDINGS PLC (STX). Of the 22 guru strategies we follow, STX rates highest using our Multi-Factor Investor model based on the ...

Below is a chart showing LVS's trailing twelve month trading history, with the $50 strike highlighted in orange: And Seagate Technology Holdings PLC (Symbol: STX) options are showing a volume of ...

Seagate (STX) came out with quarterly earnings of $2.03 per share, beating the Zacks Consensus Estimate of $1.88 per share. This compares to earnings of $0.12 per share a year ago. These figures ...

Below is Validea's guru fundamental report for SEAGATE TECHNOLOGY HOLDINGS PLC (STX). Of the 22 guru strategies we follow, STX rates highest using our Multi-Factor Investor model based on the ...

For the quarter ended December 2024, Seagate (STX) reported revenue of $2.33 billion, up 49.5% over the same period last year. EPS came in at $2.03, compared to $0.12 in the year-ago quarter.

Investors in Seagate Technology Holdings PLC (Symbol: STX) saw new options become available today, for the April 17th expiration. One of the key data points that goes into the price an option ...

Summit Insights upgraded shares of Seagate Technology (NASDAQ:STX – Free Report) from a hold rating to a buy rating in a ...

The upcoming report from Seagate (STX) is expected to reveal quarterly earnings of $1.88 per share, indicating an increase of 1466.7% compared to the year-ago period. Analysts forecast revenues of ...

Seagate Technology Holdings plc STX stock has slipped 9.9% in the past month compared with the industry and S&P 500 Composite’s decline of 4.2% and 2.7%, respectively. The stock fell 1% in the ...

Seagate Technology Holdings plc STX reported second-quarter fiscal 2025 non-GAAP earnings of $2.03 per share, beating the Zacks Consensus Estimate by 7.98%. Also, the figure was toward the high ...

Seagate Technology (NASDAQ:STX – Get Free Report) was upgraded by research analysts at Benchmark from a “hold” rating to a ...

The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3Kα inhibitor currently in a Phase 1/2 clinical trial STX ...